PRESS RELEASES

Found 226 Results
Page 1 of 23

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology


In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity   Paris (France), November 13, […]

11/13/2019

Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.


Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

11/05/2019

Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000


The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]

Tags:

10/17/2019

Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]

Tags:

10/15/2019

Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform


This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]

Tags:

10/14/2019

Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy


  Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]

Tags:

09/18/2019

Onxeo to Attend Key Investor and Scientific Conferences


Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]

Tags:

09/11/2019

Page 1 of 23
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
11/13/2019
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
11/05/2019
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
11/04/2019
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
10/17/2019
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/15/2019
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
10/14/2019
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
09/18/2019
Onxeo to Attend Key Investor and Scientific Conferences
09/11/2019
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
07/25/2019
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation
07/01/2019

Last updated on